Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and ...

A securities class action against Alexion Pharmaceuticals Inc. was “related” to an SEC investigation and should have been ...

AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately $68 ...

MULTINATIONAL pharmaceutical firm AstraZeneca (AZ) wants to conduct the majority of its clinical trials in the Philippines, ...

Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, has entered into a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo for the treatment of ...

a subsidiary of Alexion, AstraZeneca Rare Disease. Limitations may arise from the strict inclusion and exclusion criteria for participants in clinical trials. When a drug reaches the market ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

At Alexion, AstraZeneca Rare Disease, we are committed to continuing to investigate the potential role of the complement system in various diseases and accelerating the discovery and development o ...